Amedisys Home Health Of Tennessee | |
1006 Old Knoxville Road, Tazewell, Tennessee 37879 | |
(423) 626-2405 | |
Name | Amedisys Home Health Of Tennessee |
---|---|
Location | 1006 Old Knoxville Road, Tazewell, Tennessee |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 447188 |
Ownership Type | Proprietary |
Service Area Zip Codes | 37705, 37714, 37715, 37721, 37724, 37729, 37730, 37752, 37754, 37757, 37762, 37766, 37769, 37779, 37807, 37819, 37824, 37825, 37847, 37848, 37866, 37869, 37870, 37879, 37881, 37888 |
NPI Number | 1639149586 |
Organization Name | COMPREHENSIVE HOME HEALTHCARE SERVICES LLC |
Doing Business As | AMEDISYS HOME HEALTH OF TENNESSEE |
Address | 1006 Old Knoxville Road, Tazewell, TN 37879 |
Phone Number | 423-626-2405 |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
Quality Rating: |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 99.7 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 94.3 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 70.9 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 71.3 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.1 | 96.4 |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 93.7 | 79.6 |
How often patients got better at getting in and out of bed | 92.5 | 81.1 |
How often patients got better at bathing | 94 | 82.3 |
How often patients’ breathing improved | 91.3 | 82.8 |
How often patients’ wounds improved or healed after an operation | 95.2 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 91.3 | 75 |
How often home health patients had to be admitted to the hospital | 14.4 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 10 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 97.8 | 94 |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
The patient survey data of Amedisys Home Health Of Tennessee is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 92 | 88 |
Percent of patients who reported that their home health team communicated well with them | 91 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 90 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 93 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 91 | 78 |
News Archive
New research by The Times has revealed a huge variation across the UK in the cost of a common fertility drug with some high street chemists charging infertile couples up to 80 per cent more than others for private prescriptions.
Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen's macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
Amedisys Home Health Of Tennessee Location: 1006 Old Knoxville Road, Tazewell, Tennessee 37879 Ratings: Phone: (423) 626-2405 |